Research Use Disclaimer

This content is provided for educational and informational purposes only. It is not medical advice. All information is presented in a research context.

Epithalon Dosage & Protocol (Research Use)

This page does not provide dosing instructions. It explains how Epithalon dosage is typically reported in research papers, and why protocols can’t be copied out of context.

How Protocols Are Reported

Protocol Table

ElementWhat papers reportWhy it varies
Routecontext-dependentmodel and constraints
Schedulecontext-dependentobservation windows
Durationcontext-dependentstudy endpoints

FAQ

Q1: Does this page provide Epithalon dosage instructions? A1: No. This page is not medical advice and does not provide dose reporting instructions.

Q2: Why does dose reporting vary across studies? A2: Because route, schedule, duration, and endpoints differ across study designs.

Q3: Where can I read Epithalon side effects? A3: See Epithalon side effects: /peptides/epithalon/side-effects/.

References

  1. Epithalon decelerates aging and suppresses development of breast adenocarcinomas in transgenic her-2/neu mice. *2002 Aug;134(2):187-90* (2002). https://pubmed.ncbi.nlm.nih.gov/12459848/ (DOI: https://doi.org/10.1023/a:1021104819170)
  2. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. *2026 Jan 2;10(1):e25* (2026). https://pubmed.ncbi.nlm.nih.gov/41490200/ (DOI: https://doi.org/10.5435/JAAOSGlobal-D-25-00236)
  3. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. *2003 Jun;135(6):590-2* (2003). https://pubmed.ncbi.nlm.nih.gov/12937682/ (DOI: https://doi.org/10.1023/a:1025493705728)

Internal Links